SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is trending as investors discuss an overreaction to earnings, despite solid fundamentals and revenue growth, including the Alani Nu acquisition. Community members believe the dip is a buying opportunity, citing Pepsi's increased involvement and expectations for a quick rebound. Some anticipate significant gains, with potential for the stock to reach new highs soon.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending following Q3 earnings and a new $400M AI partnership with Perplexity. Community discussions revolve around the potential for a short squeeze and the long-term implications of AI integration for Snap's growth and profitability, with some expressing skepticism about the company's ability to sustain its gains.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo's stock is trending amid discussions about its future growth potential after a significant drop from previous highs. Community members are debating whether the company's AI integration and expansion into new areas like chess will offset concerns about competition from free AI translation tools. Bulls are pointing to the company's solid earnings and user growth, while bears are highlighting valuation concerns and potential disruption from AI.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health ($OSCR) is trending amidst mixed reactions to its Q3 earnings, with debates over revenue and future profitability projections. Community discussion revolves around the impact of potential ACA subsidy extensions and the company's ability to control costs and gain market share. Some traders express frustration with the stock's volatility, while others remain optimistic about its long-term potential and improving fundamentals.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD is trending amid speculation of a potential bidding war, fueled by reports of Netflix exploring an offer and the company's upcoming earnings report. Community discussions revolve around potential buyout prices, Q3 earnings expectations, and whether a deal will materialize. Some investors believe the company is undervalued, while others express skepticism about potential offers and the company's debt.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna's stock is trending amid speculation surrounding a potential acquisition or "deal of significant scope" with a major drugmaker, fueled by a report from STAT News. The community is actively discussing potential buyout prices and speculating on which company might acquire Moderna, with some citing the company's mRNA platform and oncology pipeline as key assets. Despite the excitement, concerns remain regarding upcoming earnings and the company's future growth prospects beyond COVID-19 vaccines.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending as investors discuss the company's revenue growth, potential profitability, and upcoming earnings report. Community members are also highlighting institutional ownership and potential for a buyout, with some speculating on the impact of its innovative drug delivery technologies. Anticipation surrounds upcoming presentations and potential positive catalysts for the stock.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is trending as investors react to a Piper Sandler downgrade and disappointing FY26 forecast, leading to a significant price drop. The community is debating whether the dip presents a buying opportunity or signals deeper issues with the company's growth and profitability. Discussions also include the potential impact of tariffs and the Rhode brand acquisition.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Root Inc. is trending amidst mixed sentiment after its recent earnings report, with the community debating whether growth is truly accelerating as guided. Bulls point to undervaluation compared to peers like LMND, while bears cite concerns about profitability and sustainability. Discussion also revolves around potential short squeezes and upcoming catalysts.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending amid speculation around a potential SoftBank takeover, driving community discussion on the importance of Marvell's IP and its photonics business. Some investors believe the company is undervalued with significant growth potential, while others are more cautious, citing past underperformance. The overall sentiment suggests renewed interest in MRVL, potentially fueled by AI-related growth prospects within the semiconductor sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anika Therapeutics (ANIK) Q3 Earnings and Revenues Top Estimates

Anika (ANIK) delivered earnings and revenue surprises of +100.00% and +0.06%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid, Triggering a $25 Million Milestone Payment

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid, Triggering a $25 Million Milestone Payment Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for...

Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025

Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025 Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025 PR Newswire GAITHERSBURG, Md., Oct. 30, 2025...

Novavax (NVAX) Stock Sinks As Market Gains: Here's Why

In the latest trading session, Novavax (NVAX) closed at $8.52, marking a -2.07% move from the previous day.

Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note

Novavax (NVAX) closed the most recent trading day at $8.46, moving 1.51% from the previous trading session.

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with...

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights

Novavax (NVAX) reached $8.48 at the closing of the latest trading day, reflecting a -4.83% change compared to its last close.

Novavax (NVAX) shares traded 1% higher in the pre-market session on Tuesday after its second-largest shareholder, Shah Capital, called for the sale of the company, citing persistent underperformance.Shah Capital currently owns 11.8 million shares or 7.2% of Novavax. The firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.shahcapital.com/shah-capital-calls-for-sale-of-novavax/">said</a> in a letter to the Novavax board of directors that since March 2023, its concerns have accelerated with “Nuvoxovid’s rollout slipups including this fall, timid/ineffective marketing, extremely poor capital market actions, and tremendous lack of accountability.”“Novavax’s IP and scientific capabilities will have far greater upside potential in the hands of large capable pharma entity,” Shah Capital said, while recommending an immediate formal strategic review for the sale of the company.The investor recapped several alleged missteps that have damaged the company, including critical marketing slips resulting in a small 2% Covid vaccine market share in the 2024 season for Novavax’s protein-based Nuvaxovid vaccine.Shah Capital also expressed surprise at Nuvaxovid’s market share, noting that the increasing criticism for mRNA vaccines made by Novavax’s peers should benefit Novavax’s protein-based vaccine.“With more states becoming increasingly averse to mRNA vaccines including Florida, Texas, Minnesota, Idaho, Iowa, Montana, South Carolina, Tennessee &amp; Kentucky; some of which are trying to ban mRNA altogether, we find it inconceivable as to how management has been unsuccessful gaining meaningful share given the tens of millions of senior citizens/high risk/immunocompromised individuals in just those 9 states alone. Sales are miserable for the third consecutive year,” it said.The investor also noted that awareness regarding Nuvaxovid continues to be “alarmingly low.” Shah further alleged that the “execution failure and ineffective leadership” have taken their toll on investor confidence and trust.Last year, Shah Capital waged a proxy campaign against the re-election of some directors on the company board at Novavax’s 2024 Annual Meeting, but withdrew it after the company struck a licensing agreement with Sanofi.Sanofi is Novavax’s biggest partner. In the second quarter (Q2), the $199 million received from Sanofi accounted for over 83% of Novavax’s total revenue of $239 million.<a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> is up by 7% this year but down by about 32% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wells-fargo-appoints-ceo-charlie-scharf-as-chairman-after-q3-earnings-beat-estimates/ch6mVM6R3mE">Wells Fargo Appoints CEO Charlie Scharf As Chairman After Q3 Earnings Beat Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity

Shah Capital currently owns 11.8 million shares or 7.2% of Novavax.

Equity

Shah Capital currently owns 11.8 million shares or 7.2% of Novavax.


Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

🚨 LIVE Earnings on Polymarket. 
Trading earnings just got much simpler: Will your favorite stock beat earnings – Yes or No?

Polymarket

Novavax Inc

NVAX  Earnings Call

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Current Price	$7.69
Prev Close	$7.51
Open	$7.54
Dividend Yield	0.00%
50-Day Moving Average	$8.39
Beta	1.62
Avg. Volume	4.42M
PE Ratio	3.41

52-Week High	$11.55
52-Week Low	$5.01
Market Capitalization	$1.25B
EPS (Annual)	-$1.23
Price to Book	33.14
Revenue Per Employee	$716,556.72
Enterprise Value/EBITDA	N/A

NVAX
Novavax Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVAX News

NVAXNovavax Inc